From May 29 to June 2, the American Society of Clinical Oncology (ASCO) held its annual meeting in Orlando, Florida (USA). The meeting was themed “personalizing cancer care”. The lung cancer track included several abstracts and discussions relevant to this theme. Furthermore, a number of promising new drugs were presented, and the timing of perioperative chemotherapy in patients with early stage non-small cell lung cancer (NSCLC) was debated. This short review summarizes some (but not all) of the emerging data, which may impact on the clinical care of patients with NSCLC today or in the near future.